Pharmacological aspects of calcium channel blockers

Hasso Scholz

doi:10.1007/bf00051613

journal article Jan 01, 1997

Pharmacological aspects of calcium channel blockers

Hasso Scholz

Cardiovascular Drugs and Therapy Vol. 10 No. S3 pp. 869-872 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf00051613

Topics

No keywords indexed for this article. Browse by subject →

References

25

[1]

Haas H, Härtfelder G. ?-Isopropyl-?-[(N-methyl-N-homoveratryl)-r-amino-propyl]-3,4-dimethoxyphenylacetonitril, eine Substanz mit coronargefäßerweiternden Eigenschaften. Arzneimittelforschung 1962;12:549?558.

[2]

Fleckenstein A. History of calcium antagonists. Circ Res 1983;52(Suppl I):I3-I16.

[3]

Ruzicka M, Lennen FHH. Relevance of 24 hour blood pressure profile and sympathetic activity for outcome on shortversus long-acting 1,4-dihydropyridines. Am J Hypertens 1995;9:86?94. 10.1016/0895-7061(95)00350-9

[4]

Murdoch D, Brogden RN. Sustained release of nifedipine formulations. Drugs 1991;41:737?779. 10.2165/00003495-199141050-00006

[5]

Van Zwieten PA, Pfaffendorf M. Similarities and differences between calcium antagonists: Pharmacological aspects. J Hypertens 1993;11(Suppl 1):S3-S11. 10.1097/00004872-199303001-00002

[6]

Furberg CD, Psaty BM, Meyer JV. Nifedipine, doserelated increase in mortality in patients with coronary heart disease. Circulation 1995;92:1325?1331. 10.1161/01.cir.92.5.1326

[7]

Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620?625. 10.1001/jama.1995.03530080036038

[8]

Lüscher TF, Wenzel RR, Noll G. Calcium-Antagonisten in der Kontroverse: Gibt es eine rationale Differentialtherapie? Dtsch Med Wochenschr 1996;121:523?538.

[9]

Freedman DD, Waters DD. ?Second generation? dihydropyridine calcium antagonists. Drugs 1987;34:578?598. 10.2165/00003495-198734050-00005

[10]

Nayler WG, ed. Second Generation of Calcium Antagonists. Berlin: Springer, 1991.

[11]

Godfraind T, Salomone S, Dessy C, Verhelst B, Dion R, Schoevaerts JC. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol 1992;20(Suppl 5):S34-S41. 10.1097/00005344-199206205-00006

[12]

Kelly JG, O'Malley K. Clinical pharmaco-kinetics of calcium antagonists. Clin Pharmacokinet 1992;22:416?433. 10.2165/00003088-199222060-00002

[13]

Nayler WG, ed. Amlodipine. Berlin: Springer, 1993.

[14]

Hugenholtz PG, Meyer J, eds. Nisoldipine 1987. Berlin: Springer, 1987.

[15]

Lichtlen PR, Hugenholtz PG, eds. Recent Aspects in Calcium Antagonism: Nisoldipine. Stuttgart: Schattauer, 1988.

[16]

Rousseau MF, Melin J, Benedict CR, Ahn S, Raphael D, Bornemann M. Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction. Eur Heart J 1994; 15:957?964. 10.1093/oxfordjournals.eurheartj.a060616

[17]

Rahimtoola SH, Remme WJ, eds. A symposium: Left ventricular dysfunction, calcium antagonism, and nisoldipine. Am J Cardiol 1995;75:1E?76E.

[18]

Zannad F. Clinical pharmacology of nisoldipine coat core. Am J Cardiol 1995;75:41E-45E. 10.1016/s0002-9149(99)80447-0

[19]

Saltiel E, Ellrodt AG, Monk JP, Langley MS. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1988;36:387?428. 10.2165/00003495-198836040-00002

[20]

Blychert E, Hedner T, Dahlöf C, Elmfeld D. Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients. J Cardiovasc Pharmacol 1990;15:428?435. 10.1097/00005344-199003000-00013

[21]

Peruche B. Felodipin: Ein vasoselektiver Calciumantagonist. Pharm Ztg 1992;137:3821?3825.

[22]

O'Connor CM, Belkin RN, Carson PE, et al. for The PRAISE Investigators. Circulation 1995;92(Suppl I): I-143.

[23]

Cohn JN, Ziesche SM, Loss LE, Anderson GF, and the V-HeFT Study Group. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: Results of V-HeFT VIII. Circulation 1995; 92(Suppl I):I143. 10.1161/01.cir.92.9.143

[24]

The DEFIANT Research Group, Poole-Wilson PA. Doppler flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy. Results of the DEFIANT-II study. Eur Heart Jt 1997, in press.

[25]

Godfraind T. Cardioselectivity of calcium antagonists. Cardiovasc Drugs Ther 1994;8:353?364. 10.1007/bf00877320

Cited By

85

3D-printed removable-cap device with embedded magnet for magnetic solid phase extraction

Camilla Fonseca Silva, Matheus Martins Guedes · 2026

Analytica Chimica Acta

Metrics

85

Citations

25

References

Details

Published: Jan 01, 1997
Vol/Issue: 10(S3)
Pages: 869-872
License: View

Authors

H

Hasso Scholz

Cite This Article

Hasso Scholz (1997). Pharmacological aspects of calcium channel blockers. Cardiovascular Drugs and Therapy, 10(S3), 869-872. https://doi.org/10.1007/bf00051613

Pharmacological aspects of calcium channel blockers

You May Also Like